MV Capital Management’s Telix Pharmaceuticals TLX Stock Holding History

MV Capital Management’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$865	Buy	75 +14	+23%	+$143	﹤0.01%	940
2026 Q1	$584	Buy	61 +50	+455%	+$381	﹤0.01%	948
2025 Q4	$83	Buy	+11	New	+$106	﹤0.01%	1123

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

MV Capital Management's TLX Position: Q2 2026 in Review

MV Capital Management increased its Telix Pharmaceuticals (TLX) stake by 23% in Q2 2026, buying an estimated $143 and bringing the position to 75 shares worth $865. The position accounts for ﹤0.01% of the portfolio, ranked #940.

MV Capital Management first reported a position in TLX in Q4 2025 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

MV Capital Management held 75 shares of Telix Pharmaceuticals worth $865 as of Q2 2026.
MV Capital Management bought 14 Telix Pharmaceuticals shares in Q2 2026, an estimated $143.
Telix Pharmaceuticals made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #940 holding.
MV Capital Management first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.